Are Breast Cancer Subtypes Prognostic for Nodal Involvement and Associated with Clinicopathologic Features at Presentation in Early-Stage Breast Cancer?

被引:44
|
作者
Jones, Tiffanie [1 ]
Neboori, Hanmanth [2 ]
Wu, H. [2 ]
Yang, Qifeng [3 ]
Haffty, Bruce G. [2 ]
Evans, Susan [1 ]
Higgins, Susan [1 ]
Moran, Meena S. [1 ]
机构
[1] Yale Univ, Sch Med, New Haven, CT 06520 USA
[2] UMDNJ Robert Wood Johnson Sch Med, New Brunswick, NJ USA
[3] Shangdong Univ, Jinan, Peoples R China
关键词
TRIPLE-NEGATIVE PHENOTYPE; BASAL-LIKE SUBTYPE; MOLECULAR SUBTYPE; CONSERVATION THERAPY; AXILLARY DISSECTION; HORMONE-RECEPTOR; SURVIVAL; OUTCOMES; BIOPSY; WOMEN;
D O I
10.1245/s10434-013-2994-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer subtypes (BCS) determined from immunohistochemical staining have been correlated with molecular subtypes and associated with prognosis and outcomes, but there are limited data correlating these BCS and axillary node involvement. This study was conducted to assess whether BCS predicted for nodal metastasis or was associated with other clinicopathologic features at presentation. Patients with stage I/II disease who underwent breast-conserving surgery and axillary surgical assessment with available tissue blocks underwent a institutional pathological review and construction of a tissue microarray. The slides were stained for estrogen receptor, progesterone receptor, and HER-2/neu (HER-2) for classification into BCS. Nodal involvement and other clinicopathologic features were analyzed to assess associations between BCS and patient and tumor characteristics. Outcomes were calculated a function of BCS. The study cohort consisted of 453 patients (luminal A 48.6 %, luminal B 16.1 %, HER-2 11.0 %, triple negative 24.2 %), of which 22 % (n = 113) were node positive. There were no significant associations with BCS and pN stage, node positivity, or absolute number of nodes involved (p > 0.05 for all). However, there were significant associations with subtype and age at presentation (p < 0.001), method of detection (p = 0.049), tumor histology (p < 0.001), race (p = 0.041), and tumor size (pT stage, p < 0.001) by univariate and multivariate analysis. As expected, 10-year outcomes differed by BCS, with triple negative and HER-2 subtypes having the worse overall (p = 0.03), disease-free (p = 0.03), and distant metastasis-free survival (p < 0.01). There is a significant association between BCS and age, T stage, histology, method of detection, and race, but no associations to predict nodal involvement. If additionally validated, these findings suggest that BCS may not be a useful prognostic variable for influencing regional management considerations.
引用
收藏
页码:2866 / 2872
页数:7
相关论文
共 50 条
  • [31] Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
    Alexandre Prieur
    Andrew Harper
    Momtafin Khan
    Bérengère Vire
    Dominique Joubert
    Léa Payen
    Karen Kopciuk
    BMC Cancer, 23
  • [32] Radiation Therapy for Early-Stage Breast Cancer after Breast-Conserving Surgery
    Buchholz, Thomas A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (01) : 63 - 70
  • [33] The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer
    Ordu, Cetin
    McGuire, Kandace
    Alco, Gul
    Pilanci, Kezban Nur
    Koksal, Ulkuhan I.
    Elbuken, Filiz
    Erdogan, Zeynep
    Agacayak, Filiz
    Ilgun, Serkan
    Sarsenov, Dauren
    Ozturk, Alper
    Igdem, Sefik
    Okkan, Sait
    Eralp, Yesim
    Dincer, Maktav
    Ozmen, Vahit
    CUREUS, 2016, 8 (06):
  • [34] Breast surgery for young women with early-stage breast cancer Mastectomy or breast-conserving therapy?
    Sun, Zhi-Hong
    Chen, Chuang
    Kuang, Xin-Wen
    Song, Jun-Long
    Sun, Sheng-Rong
    Wang, Wei-Xing
    MEDICINE, 2021, 100 (18) : E25880
  • [35] Nationwide Trends in Mastectomy for Early-Stage Breast Cancer
    Kummerow, Kristy L.
    Du, Liping
    Penson, David F.
    Shyr, Yu
    Hooks, Mary A.
    JAMA SURGERY, 2015, 150 (01) : 9 - 16
  • [36] Goal disturbance in early-stage breast cancer survivors
    Haydon, Marcie D.
    Stanton, Annette L.
    Ganz, Patricia A.
    Bower, Julienne E.
    JOURNAL OF PSYCHOSOCIAL ONCOLOGY, 2019, 37 (04) : 478 - 493
  • [37] Controversies in Radiation Oncology for Early-Stage Breast Cancer
    Bellon, Jennifer R.
    Golshan, Mehra
    Solin, Lawrence J.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (10) : 3213 - 3218
  • [38] Preoperative PET/CT in early-stage breast cancer
    Bernsdorf, M.
    Berthelsen, A. K.
    Wielenga, V. T.
    Kroman, N.
    Teilum, D.
    Binderup, T.
    Tange, U. B.
    Andersson, M.
    Kjaer, A.
    Loft, A.
    Graff, J.
    ANNALS OF ONCOLOGY, 2012, 23 (09) : 2277 - 2282
  • [39] Models of care for early-stage breast cancer in Canada
    Madarnas, Y.
    Joy, A. A.
    Verma, S.
    Sehdev, S.
    Lam, W.
    Sideris, L.
    CURRENT ONCOLOGY, 2011, 18 : S10 - S19
  • [40] Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
    Prieur, Alexandre
    Harper, Andrew
    Khan, Momtafin
    Vire, Berengere
    Joubert, Dominique
    Payen, Lea
    Kopciuk, Karen
    BMC CANCER, 2023, 23 (01)